The Effect of High Dose Salbutamol on Muscle Performance

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

University of Copenhagen

Information provided by:

Bispebjerg Hospital

ClinicalTrials.gov Identifier:

NCT01415596

First received: August 11, 2011

Last updated: NA

Last verified: March 2011

History: No changes posted

Tracking Information
First Received Date ^ICMJE	August 11, 2011
Last Updated Date	August 11, 2011
Start Date ^ICMJE	August 2011
Estimated Primary Completion Date	August 2012 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: August 11, 2011)	Muscle power
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE (submitted: August 11, 2011)	Muscle recovery
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	The Effect of High Dose Salbutamol on Muscle Performance
Official Title ^ICMJE	The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males
Brief Summary	Many athletes use beta2-agonists as treatment of airway hyperresponsiveness during exercise. High dose beta2-agonists may have an ergogenic effect on exercise performance. We hypotheis that the beta2-agonist, salbutamol, taken in high doses can improve muscle power and recovery during exercise in well-trained athletes.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Not Provided
Study Design ^ICMJE	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator)
Condition ^ICMJE	Ergogenic Effects of Salbutamol in Healthy Males
Intervention ^ICMJE	Drug: salbutamol Drug: Placebo
Study Arm (s)	Placebo Comparator: Placebo Intervention: Drug: Placebo Active Comparator: Salbutamol Intervention: Drug: salbutamol
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Active, not recruiting
Enrollment ^ICMJE	20
Estimated Completion Date	August 2013
Estimated Primary Completion Date	August 2012 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Males age 18-45 training frequency > 10 hrs/wk informed consent Exclusion Criteria: smoker or former smoker chronic diseases, as well as asthma allergy to the study drugs intake of any form of medicin or inhibited drugs during the study use of beta2-agonist 14 days before the intervention
Gender	Male
Ages	18 Years to 45 Years
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Denmark

Administrative Information
NCT Number ^ICMJE	NCT01415596
Other Study ID Numbers ^ICMJE	SALMUS2011
Has Data Monitoring Committee	Yes
Responsible Party	Vibeke Backer, Bispebjerg Hospital
Study Sponsor ^ICMJE	Bispebjerg Hospital
Collaborators ^ICMJE	University of Copenhagen
Investigators ^ICMJE	Not Provided
Information Provided By	Bispebjerg Hospital
Verification Date	March 2011
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top